View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 27, 2020

Bioneb receives £220m investment commitment from Gem Group

UK-based biotech company Bioneb has secured a funding commitment of up to £220m from American investment firm GEM Global Yield.

UK-based biotech company Bioneb has secured a funding commitment of up to £220m from American investment firm GEM Global Yield.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

According to the agreement, New York-based GEM will make the investment over a period of 36 months.

Bioneb will use the funds to support the ongoing research and development activities for its Food and Drug Administration (FDA)-approved ultrasonic vibrating mesh drug delivery devices, medical formulations and FDA clinical trials.

The company also plans to scale up the production of the devices at its FDA-approved Vietnamese and Taipei facilities.

Subsequently, the production, distribution, and marketing of the formulations at the Netherlands, Canadian, and Californian facilities are also expected to increase.

Bioneb said it will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation.

In accordance with the deal, the company will issue warrants to GEM to obtain approximately 9.9% of its outstanding common stock on a fully diluted basis.

The warrants will have an exercise price per share equal to the pro-rata portion of £300m valuation for the company.

Additionally, it will pay a fee equal to 2% of the size of capital commitment within 12 months.

Bioneb CEO and founder Nick Havercroft said: “This agreement with GEM helps to secure funding for continued growth and development of the company as we attempt to bring to market our breakthrough Covid suppressant formulation, which is having remarkable results in suppressing and eliminating the Covid virus if used in the early stages of any infection.

“The proven results, case studies, time kill graphs, and curves show that Bioneb’s patent-pending anti-viral formulation eliminates any virus and bacteria when inhaled with the drug delivery device or disbursed into built in environments such as schools, offices or mass transport systems, using the same technology in a sub-micron diffuser distribution unit.”

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network